To address concerns about the long-term safety of using dopamine agonists to treat patients with hyperprolactinemia Valassi and colleagues carried out a systematic review of the literature. Although the results show no increased risk of valvular heart disease, lengthy prospective follow-up studies are needed in patients requiring long-term high dose regimens.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W. & Garbe, E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356, 29–38 (2007).
Zanettini, R. et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356, 39–46 (2007).
Van Camp, G. et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363, 1179–1183 (2004).
Valassi, E., Klibanski, A. & Biller, B. M. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J. Clin. Endocrinol. Metab. 95, 1025–1033 (2010).
Lafeber, M. et al. Absence of major fibrotic events in hyperprolactinemic patients treated with cabergoline. Eur. J. Endocrinol. 162, 667–675 (2010).
Colao, A. et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J. Clin. Endocrinol. Metab. 93, 3777–3784 (2008).
Kars, M. et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J. Clin. Endocrinol. Metab. 93, 3348–3356 (2008).
Wakil, A., Rigby, A. S., Clark, A. L., Kallvikbacka-Bennett, A. & Atkin, S. L. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur. J. Endocrinol. 159, R11–R14 (2008).
Singh, J. P. et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am. J. Cardiol. 83, 897–902 (1999).
Kars, M., Pereira, A. M., Bax, J. J. & Romijn, J. A. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur. J. Endocrinol. 159, 363–367 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Droogmans, S., Van Camp, G. Valvulopathy in patients treated for hyperprolactinemia?. Nat Rev Endocrinol 6, 357–358 (2010). https://doi.org/10.1038/nrendo.2010.90
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2010.90
